Tumour heterogeneity and cancer cell plasticity

Nature

Volumn 501, Issue 7467, 2013, Pages 328-337

  Meacham, Corbin E ^a   Morrison, Sean J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; CD34 ANTIGEN; CD38 ANTIGEN; CELL ADHESION MOLECULE; GANCICLOVIR; GROWTH FACTOR; IMATINIB; MERCAPTOPURINE; NESTIN; TAMOXIFEN; TEMOZOLOMIDE; THYMIDINE KINASE; TIOGUANINE;

CANCER; DISEASE; PHENOTYPE; PLASTICITY; TUMOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL FATE; CELL HETEROGENEITY; CELL TRANSPLANTATION; CEREBELLUM; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLONAL EVOLUTION; COLORECTAL CANCER; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; LEUKEMOGENESIS; MEDULLOBLASTOMA; MYELOID LEUKEMIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; XENOTRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CLONAL EVOLUTION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84884377472     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12624     Document Type: Review

References (115)

1. Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793-4807 (2008)
2. Kummermehr, J. & Trott, K.-R. in Stem Cells (ed. Potten, C. S.) 363-399 (Academic, 1997)
3. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001)
4. Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829 (2009)
5. Clevers, H. The cancer stem cell: premises, promises and challenges. Nature Med. 17, 313-319 (2011)
6. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006)
7. Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783 (2009)
8. Oravecz-Wilson, K. I. et al. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell 16, 137-148 (2009)
9. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008)
10. Balic, M. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621 (2006)
11. Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012)
12. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976)
13. Charles, N. et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6, 141-152 (2010)
14. Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007)
15. Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510-523 (2010). This article reports that many phenotypically diverse melanoma cells are capable of forming tumours that recapitulate the surface marker heterogeneity of the tumour from which they derive, suggesting that there may not be a hierarchy of tumorigenic and non-tumorigenic cells in melanoma
16. Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594 (2010)
17. Pinner, S. et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 69, 7969-7977 (2009)
18. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010). This article reports that the acquisition of tolerance to therapeutics is transient and reversible in lung cancer cell lines raising the possibility that there are epigenetic mechanisms of therapy resistance that do not necessarily have anything to do with stem-cell identity or static hierarchies
19. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012). Using a mouse model of malignant glioma, the authors of this study report that selective ablation of Nestin+ glioma cells suggests that a relatively quiescent cell population sustains tumour growth after therapy
20. Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature 488, 527-530 (2012). Lineage tracing in a mouse model of benign papilloma shows that only a fraction of papilloma cells sustainably contribute to tumour growth, although the frequency of such cells increases drastically on progression to squamous cell carcinoma
21. Schepers, A. G. et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012). Fate mapping of Lgr5+ cells in intestinal adenomas shows that these cells contribute to tumour growth while also forming Lgr5? progeny, raising the possibility that some adenomas are hierarchically organized
22. Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2013). This study shows that both Lgr5+ and Lgr5? cells within intestinal adenomas are capable of forming tumours that are heterogeneous for Lgr5, suggesting that some adenomas may not be hierarchically organized
23. Nakanishi, Y. et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nature Genet. 45, 98-103 (2013)
24. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011)
25. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012). By sequencing samples from patients with AML before and after therapy, this study shows that new genetic variants commonly emerge after therapy, suggesting that therapy resistance is commonly determined by genetic variants
26. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008)
27. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011)
28. Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886-895 (2012)
29. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994)
30. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997)
31. Wang, J. C. et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91, 2406-2414 (1998)
32. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003)
33. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004)
34. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007)
35. O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007)
36. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007)
37. Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037 (2007)
38. Curley, M. D. et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27, 2875-2883 (2009)
39. Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320 (2008)
40. Stewart, J. M. et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl Acad. Sci. USA 108, 6468-6473 (2011). This study demonstrates that CD133 enriches tumorigenic cells in only a subset of ovarian cancers and that even in these tumours the effectiveness of the marker changes on passaging
41. Kennedy, J. A., Barabe, F., Poeppl, A. G., Wang, J. C. & Dick, J. E. Comment on ?Tumor growth need not be driven by rare cancer stem cells?. Science 318, 1722 (2007)
42. Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7, 118-130 (2007)
43. Taussig, D. C. et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112, 568-575 (2008)
44. Notta, F. et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469, 362-367 (2011)
45. Chiu, P. P., Jiang, H. & Dick, J. E. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 116, 5268-5279 (2010)
46. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593-598 (2008)
47. Ishizawa, K. et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 7, 279-282 (2010)
48. Buchstaller, J., McKeever, P. E. & Morrison, S. J. Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell 21, 240-252 (2012)
49. Manz, M. G. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 26, 537-541 (2007)
50. Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971 (2004)
51. Kleinsmith, L. J. & Pierce, G. B. Multipotentiality of single embryonal carcinoma cells. Cancer Res. 24, 1544-1551 (1964)
52. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006)
53. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006)
54. Neering, S. J. et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110, 2578-2585 (2007)
55. Vaillant, F. et al. The mammary progenitor marker CD61/?3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 68, 7711-7717 (2008)
56. Zhang, M. et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 68, 4674-4682 (2008)
57. Read, T. A. et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15, 135-147 (2009)
58. Ward, R. J. et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 69, 4682-4690 (2009)
59. Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007)
60. Held, M. A. et al. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 70, 388-397 (2010)
61. Williams, R. T., den Besten, W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 21, 2283-2287 (2007)
62. Rehe, K. et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol. Med. 5, 38-51 (2013)
63. Feuring-Buske, M. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in ? 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17, 760-763 (2003)
64. Notta, F., Doulatov, S. & Dick, J. E. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood 115, 3704-3707 (2010)
65. Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Med. 17, 1086-1093 (2011). The authors of this study demonstrated that the frequency and surface marker phenotype of leukaemic stem cells varied among samples from 16 patients
66. Boiko, A. D. et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466, 133-137 (2010)
67. Civenni, G. et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71, 3098-3109 (2011)
68. Chen, R. et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17, 362-375 (2010)
69. Joo, K. M. et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest. 88, 808-815 (2008)
70. Wang, J. et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122, 761-768 (2008)
71. Beier, D. et al. CD133+ and CD133? glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67, 4010-4015 (2007)
72. Sarry, J. E. et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R?c-deficient mice. J. Clin. Invest. 121, 384-395 (2011)
73. Taussig, D. C. et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34? fraction. Blood 115, 1976-1984 (2010)
74. Curtis, S. J. et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 7, 127-133 (2010)
75. Gibson, P. et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468, 1095-1099 (2010)
76. Johnson, R. A. et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632-636 (2010)
77. Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029-3035 (2003)
78. Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268 (2006)
79. Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596 (2004)
80. Krivtsov, A. V. et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 27, 852-860 (2013)
81. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012)
82. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548 (2013)
83. Mascre, G. et al. Distinct contribution of stem and progenitor cells to epidermal maintenance. Nature 489, 257-262 (2012)
84. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007)
85. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644 (2011)
86. Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nature Rev. Cancer 12, 323-334 (2012)
87. Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090-1098 (2012)
88. Schuh, A. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120, 4191-4196 (2012)
89. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012)
90. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012)
91. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012)
92. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010)
93. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010)
94. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008)
95. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012)
96. le Viseur, C. et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14, 47-58 (2008)
97. Dylla, S. J. et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3, e2428 (2008)
98. de Thé, H. & Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Rev. Cancer 10, 775-783 (2010)
99. Piccirillo, S. G. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765 (2006)
100. Gross, R. E. et al. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron 17, 595-606 (1996)
101. Thiele, C. J., Reynolds, C. P. & Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313, 404-406 (1985)
102. Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N. Engl. J. Med. 341, 1165-1173 (1999)
103. Garraway, L. A. & Janne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012)
104. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013)
105. Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med. 19, 368-371 (2013)
106. Meyer, J. A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genet. 45, 290-294 (2013)
107. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340 (1999)
108. Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409 (2011)
109. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002)
110. Jiang, X. et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21, 926-935 (2007)
111. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003)
112. Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58-60 (2007)
113. Savona, M. & Talpaz, M. Getting to the stem of chronic myeloid leukaemia. Nature Rev. Cancer 8, 341-350 (2008)
114. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001)
115. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).